Standing Ovation, a company specializing in the production of proteins through precision fermentation, has announced a $34.2 million (€30 million) Series B funding round, including $28.5 million (€25 million) in equity.
This round was jointly led by the Ecotechnologies 2 fund, managed on behalf of the French government by Bpifrance as part of the France 2030 initiative, and Crédit Mutuel Innovation, alongside existing investors – Astanor, Groupe Bel, Seventure Partners, GoodStartUp, and Big Idea Ventures – joined by Danone Ventures, Angelor, Newtree, and Noshaq.
This capital increase is complemented by $5.7 million (€5 million) in non-dilutive financing from Bpifrance and a leading banking syndicate.
The funds raised, following a €16 million Series A round, will finance the commercial ramp-up of Standing Ovation proteins in the United States and, from the end of 2027, in Europe and Asia.
Legal advisers on this deal:
Walter Billet Avocats had advised Standing Ovation with a team composed of partner Fabien Billet and Miguel Goncalves.
The investors were advised by Chammas & Marcheteau (Lola Chammas, partner, Arys Serdjanian and Flore Maxence Le Blanc), Fieldfisher (Denis Barat, partner) and Marignan Partners (Benjamin Prévost and Jordan Jablonka, partners).